Events

This webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be conditionally classified as Schedule 8 (controlled drug) in the Poisons Standard.

This webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) when prescribed by a psychiatrist.

In this webinar we will provide an update on the Australian UDI implementation and discuss the challenges and benefits of having UDI in healthcare and the role of hospitals and other healthcare providers in relation to using UDI.

Advisory Committee on Vaccines (ACV) meeting

Advisory Committee on Medicines (ACM) meeting

This webinar will explain labelling requirements for finished MCP in detail.

Advisory Committee on Vaccines (ACV) meeting

This webinar will guide you through the process of charging for regulatory activities, the medicinal cannabis funding model and the fees and charges structure and amounts proposed to commence on 1 July 2023.

The final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.

The final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.

This is the second in a series of three educational webinars outlining what regulatory actions are required as a result of changes under the EU MDR, with a focus on manufacturer evidence and variations to the ARTG.

Presentation on the new formatting and structure of the Poisons Standard

This webinar will focus on how the changes under the EU MDR will affect manufacturer evidence and variations to the ARTG.

Changes to the formatting and structure of the Poisons Standard will come into effect from 1 February 2023

This is the first in a series of three educational webinars outlining what regulatory actions are required as a result of changes under the EU MDR.

This webinar will outline what regulatory actions are required as a result of changes under the EU MDR, and how the TGA will streamline the transition.

Therapeutic Goods Advertising Consultative Committee

Advisory Committee on Medicines (ACM) meeting

The purpose of this webinar was to help sponsors understand how to use the Listed Medicines Evidence Guidelines to compile a robust evidence package that supports the efficacy of their listed medicine.

The 40th meeting of the Advisory Committee on Medicines Scheduling (ACMS #40), November 2022.

The 35th meeting of the Advisory Committee on Chemicals Scheduling (ACCS #35), November 2022.

Advisory Committee on Biologicals (ACB) meeting

The 32nd joint meeting of the Advisory Committee on Medicines Scheduling and Chemicals Scheduling (Joint ACMS-ACCS #32), November 2022.

Advisory Committee on Complementary Medicines (ACCM) meeting

Presentation at the RACI Pharmaceutical Science Group (NSW) Seminar/Webinar, information for manufacturers of medicinal products on Computerised Systems - establishing and maintaining data integrity